3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 2,823,367 | 2,603,703 |
売掛金 | 463,933 | 336,054 |
有価証券 | 1,118,245 | 3,904,102 |
商品及び製品 | 132,991 | 127,359 |
仕掛品 | 61,118 | 69,659 |
原材料及び貯蔵品 | 76,248 | 79,848 |
その他 | 220,821 | 213,173 |
貸倒引当金 | △283 | △4,539 |
流動資産合計 | 4,896,441 | 7,329,361 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 58,819 | 61,160 |
減価償却累計額 | △31,407 | △36,579 |
建物及び構築物(純額) | 27,411 | 24,581 |
機械装置及び運搬具 | 199,729 | 239,071 |
減価償却累計額 | △57,552 | △92,423 |
機械装置及び運搬具(純額) | 142,176 | 146,648 |
工具、器具及び備品 | 124,947 | 196,559 |
減価償却累計額 | △52,823 | △85,379 |
工具、器具及び備品(純額) | 72,124 | 111,179 |
有形固定資産合計 | 241,713 | 282,409 |
無形固定資産 | | |
のれん | 8,139 | 5,426 |
その他 | 18,699 | 8,421 |
無形固定資産合計 | 26,838 | 13,847 |
投資その他の資産 | | |
投資有価証券 | 4,403,537 | 1,914,189 |
繰延税金資産 | 55,322 | 59,155 |
その他 | 55,539 | 58,402 |
貸倒引当金 | △8,637 | △5,049 |
投資その他の資産合計 | 4,505,762 | 2,026,697 |
固定資産合計 | 4,774,314 | 2,322,954 |
資産合計 | 9,670,755 | 9,652,315 |
| | (単位:千円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 131,109 | 141,808 |
未払金 | 101,159 | 124,212 |
未払法人税等 | 24,796 | 25,537 |
契約負債 | 42,437 | 40,672 |
前受金 | 113,602 | 116,629 |
賞与引当金 | 11,080 | 8,710 |
その他 | 216,399 | 159,663 |
流動負債合計 | 640,585 | 617,234 |
固定負債 | | |
繰延税金負債 | 35,206 | 176,741 |
資産除去債務 | 9,081 | 9,125 |
その他 | 935 | 2,487 |
固定負債合計 | 45,223 | 188,354 |
負債合計 | 685,808 | 805,589 |
純資産の部 | | |
株主資本 | | |
資本金 | 2,688,926 | 2,720,149 |
資本剰余金 | 6,244,884 | 6,276,107 |
利益剰余金 | 58,294 | △533,398 |
自己株式 | △916 | △916 |
株主資本合計 | 8,991,188 | 8,461,940 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | △13,677 | 325,433 |
為替換算調整勘定 | 7,435 | 59,352 |
その他の包括利益累計額合計 | △6,242 | 384,785 |
純資産合計 | 8,984,946 | 8,846,726 |
負債純資産合計 | 9,670,755 | 9,652,315 |
E2758549780株式会社リプロセルReproCELL Incorporated通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse497802026-05-14497802026-03-31497802025-04-012026-03-31497802025-03-31497802024-04-012025-03-31497802024-03-31497802026-03-31jpcrp_cor:ReportableSegmentsMember497802026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802025-04-012026-03-31jpcrp_cor:ReportableSegmentsMember497802025-04-012026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802025-03-31jpcrp_cor:ReportableSegmentsMember497802025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember497802024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802026-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802026-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802025-04-012026-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802025-04-012026-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802025-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802025-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802024-04-012025-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802024-04-012025-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802026-03-31jpcrp_cor:ReconcilingItemsMember497802025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember497802025-03-31jpcrp_cor:ReconcilingItemsMember497802024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember497802025-03-31jppfs_cor:SubscriptionRightsToSharesMember497802024-04-012025-03-31jppfs_cor:ShareholdersEquityMember497802024-04-012025-03-31jppfs_cor:CapitalStockMember497802026-03-31jppfs_cor:ShareholdersEquityMember497802026-03-31jppfs_cor:CapitalStockMember497802026-03-31jppfs_cor:CapitalSurplusMember497802026-03-31jppfs_cor:RetainedEarningsMember497802024-04-012025-03-31jppfs_cor:CapitalSurplusMember497802024-04-012025-03-31jppfs_cor:RetainedEarningsMember497802024-04-012025-03-31jppfs_cor:TreasuryStockMember497802024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember497802024-03-31jppfs_cor:ShareholdersEquityMember497802024-03-31jppfs_cor:CapitalStockMember497802024-03-31jppfs_cor:CapitalSurplusMember497802024-03-31jppfs_cor:RetainedEarningsMember497802024-03-31jppfs_cor:TreasuryStockMember497802024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802025-03-31jppfs_cor:CapitalSurplusMember497802026-03-31jppfs_cor:TreasuryStockMember497802026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802025-04-012026-03-31jppfs_cor:ShareholdersEquityMember497802025-04-012026-03-31jppfs_cor:CapitalStockMember497802025-04-012026-03-31jppfs_cor:CapitalSurplusMember497802025-04-012026-03-31jppfs_cor:RetainedEarningsMember497802025-04-012026-03-31jppfs_cor:TreasuryStockMember497802025-04-012026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802025-04-012026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802025-04-012026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802025-03-31jppfs_cor:ShareholdersEquityMember497802025-03-31jppfs_cor:CapitalStockMember497802025-03-31jppfs_cor:RetainedEarningsMember497802025-03-31jppfs_cor:TreasuryStockMember497802025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802024-03-31jppfs_cor:SubscriptionRightsToSharesMemberxbrli:pureiso4217:JPY